Femoral-Peroneal Bypass: Definition and Clinical Context
A femoral-peroneal bypass is a surgical revascularization procedure that creates an alternate blood flow pathway from the femoral artery to the peroneal artery using a graft conduit, typically performed in patients with severe peripheral arterial disease (PAD) when the peroneal artery is the only viable outflow vessel to the foot. 1
Anatomical and Technical Considerations
The peroneal artery serves as the target vessel when both the anterior and posterior tibial arteries are occluded or unsuitable for bypass, making it the sole remaining option for distal revascularization in patients with critical limb-threatening ischemia (CLTI). 1, 2
Graft Selection
- Autogenous vein (typically greater saphenous vein) is the mandatory conduit choice for femoral-tibial and femoral-peroneal bypasses in CLTI patients. 3
- If no autogenous vein is available from the ipsilateral or contralateral leg or arms, prosthetic femoral-tibial bypass with adjunctive procedures (arteriovenous fistula or vein interposition/cuff) should be used only when amputation is imminent. 3
- Synthetic graft material should never be used for femoral-tibial or femoral-peroneal bypasses in claudication patients due to unacceptably poor patency rates. 3, 4
Clinical Indications
Primary Indication: Critical Limb-Threatening Ischemia
Femoral-peroneal bypass is indicated for patients with CLTI (rest pain, tissue loss, or gangrene) when the peroneal artery represents the only patent tibial vessel with continuous outflow to the foot. 3, 1
- The procedure is performed as an alternative to primary amputation in patients with severe ischemia. 1
- Early revascularization is recommended as soon as possible in CLTI patients to maximize limb salvage. 3
Rare Consideration for Claudication
Femoral-peroneal bypass may be considered in rare instances for severe claudication, but only when constructed with autogenous vein and after failure of optimal medical therapy and exercise rehabilitation. 3
Expected Outcomes
Patency and Limb Salvage Rates
Historical data demonstrates that femoroperoneal bypass achieves functional graft patency in approximately 64% of cases, with limb salvage in 35.7% of patients, which is notably lower than femorotibial bypass (70.8% limb salvage). 1
More contemporary evidence shows:
- At 12 months, surgical peroneal bypass achieves primary patency of 47.9%, primary assisted patency of 63.6%, and secondary patency of 74.2%. 2
- Wound healing occurs in approximately 52.6% of patients at 1 year. 2
- Freedom from major amputation is 81.5% at 1 year. 2
Important Caveat on Graft Patency Without Limb Salvage
A critical pitfall of femoroperoneal bypass is that 44.4% of patent grafts fail to achieve limb salvage, compared to only 4.2% with femorotibial bypass. 1 This suggests that even with successful revascularization, the peroneal artery's anatomical position may provide suboptimal perfusion to the foot in some patients.
Comparison with Endovascular Alternatives
Endovascular peroneal artery intervention provides similar wound healing (37.7% at 1 year) and limb salvage rates (74.7% freedom from major amputation at 1 year) compared to surgical bypass, but with significantly lower patency rates. 2
- Primary patency for endovascular intervention is only 23.4% at 12 months versus 47.9% for bypass. 2
- Endovascular intervention has lower perioperative complication rates (no myocardial infarctions versus 4.5% with bypass, and 4.4% incisional complications versus 13.0% with bypass). 2
- In appropriately selected high-risk surgical patients, endovascular peroneal intervention may be considered as first-line therapy, particularly in those with increased surgical risk or inadequate autogenous veins. 3, 2
Surgical Principles for Multilevel Disease
When combined inflow and outflow disease exists, inflow lesions must be addressed first. 3, 5 If CLTI symptoms or infection persist after inflow revascularization, then the outflow procedure (such as femoral-peroneal bypass) should be performed. 3, 5
Postoperative Management
All patients undergoing revascularization for CLTI should be placed on antiplatelet therapy indefinitely unless contraindicated. 3
Patients with autogenous vein bypasses require periodic evaluations for at least 2 years that include: